Loading viewer...
investor_presentation
Format: PDF investor_presentation
INVESTOR DECK INVESTOR DECK INVESTOR DECK SEEKING GENE THERAPY CURES
SEEKING GENE THERAPY CURES2DISCLAIMER
Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations
regarding its guidance for 2022 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket maydevelop, to treat
Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD),and Danon Disease, and the safety, effectiveness and
timing of related pre-clinical studies and clinical trials and related data readouts, may constitute forward-looking statements for the purposes of the
safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words suchas "believe,"
"expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the
negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot
guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various
important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to
ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our
expectations regarding when clinical trial sites will resume normal business operations, our expectations regarding the delays and impact of COVID-
19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated
trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product
candidates, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the
outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "RiskFactors" in Rocket’s
Annual Report on Form 10-K for the year ended December 31, 2021, filed February 28, 2022 with theSEC and subsequent filings with the SEC
including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such
statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise.3
ABOUT ROCKET PHARMACEUTICALS
“For the first time in history, we are discussing not
Preview truncated — download the full document for the complete content.
conference
45 Pages
investor_presentation
20 Pages
Superior Plus
SAPPE Performance Highlights 2023 Direction 2024
investor_presentationinvestor_presentation
57 Pages
SAPPE PUBLIC COMPANY LIMITED